NEW YORK — BforCure said last week that it has received CE-IVD marking for its Bfast SARS-CoV-2 RT-PCT kit.
The kit is designed to detect two SARS-CoV-2 genes. It runs on the company's Chronos Dx in vitro diagnostic PCR platform and provides results within 15 minutes.
Last month, Paris-based BforCure raised €2 million ($2.3 million) from ID-Solutions to adapt Chronos Dx to detect cancers.